Could homocysteine, angiotensin and alamandine be used as potential biomarkers in management of COVID-19?


  • Sibasish Sahoo All India Institute of Medical Sciences, Kalyani, West Bengal, India
  • Sasikala T. ESIC Medical College, Sanathnagar, Hyderabad, India
  • Sampath Kumar V. ESIC Medical College, Sanathnagar, Hyderabad, India
  • Lakshmanna N. Sri Venkateswara Institute of Medical Sciences, Tirupati, India



COVID-19, Homocysteine, Angiotensin, Alamandine


The corona virus is now known as the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). Risk predictors and novel predictors associated with COVID-19 is required to enable the risk stratification, guide interventional studies to target patients at enhanced risk of developing severe disease risk and optimize the allocation of limited human and technical resources in the ongoing pandemic all over the globe. The present review focused on potential laboratory biomarkers associated with COVID-19. We carried out an electronic search in Medline (PubMed central), Scopus, Web of Science and using the keywords laboratory, biomarkers, novel biomarkers, corona virus 2019 or COVID-19. We observed that limited data were found that related to homocysteine and angiotensin II in COVID-19 patients. Hence original research on these novel biomarkers which associated with the complication of COVID-19 might be given new clues especially that mediate anti-inflammatory and anti-fibrotic effects leading to cardiovascular, renal-protective actions. The present review proposed by the available literature, these predictors might be the potent biomarkers to improve management of corona virus. Further, large cohort studies will be required to support conclusions of present review.


Pierce JD, McCabe S, White N, Clancy RL. Biomarkers: an important clinical assessment tool. Am J Nurs. 2012;112(9):52-8.

Sasikala T, Mukherjee B, Sahoo S, Sahoo AK. Vitamin-D deficiency as a predisposing cause for COVID-19 morbidities. JCR. 2020;7(8):2522-6.

Gong J, Dong H, Xia SQ, Huang Z, Wang D, Zhao Y, et al. Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19 pneumonia. Medrxiv, 2020.

Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020;506:145-8.

Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chim Acta. 2020;505:190-1.

Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015;14:6.

Balint B, Jepchumba VK, Gueant JL, Guéant-Rodriguez R. Mechanisms of homocysteine-induced damage to the endothelial, medial and adventitial layers of the arterial wall. Biochimie. 2020;173:100-6.

Pushpakumar S, Kundu S, Sen U. Endothelial dysfunction: the link between homocysteine and hydrogen sulfide. Curr Med Chem. 2014;21(32):3662-72.

Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997;277(22):1775-81.

Faeh D, Chiolero A, Paccaud F. Homocysteine as a risk factor for cardiovascular disease: should we (still) worry about? Swiss Med Wkly. 2006;136(47-48):74-56.

Guo H, Chi J, Xing Y, Wang P. Influence of folic acid on plasma homocysteine levels & arterial endothelial function in patients with unstable angina. Indian J Med Res. 2009;129(3):279-84.

Baszczuk A, Kopczynski Z. Hyperhomocysteinemia in patients with cardiovascular disease. Postepy Hig Med Dosw. 2014;68:579-89.

Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Indian Heart J. 2000;52(7):18-26.

Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417(6891):822-8.

Ponti G, Ruini C, Tomasi A. Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19. Medical Hypotheses. 2020;143:109859.

Ibrahimagić OC, Smajlović D, Dostović Z, Vidović M. Comment on an article: homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19. Medical Hypotheses. 2020;143:110107.

Singh Y, Gupta G, Kazmi I, Al‐Abbasi FA, Negi P, Chellappan DK, et al. SARS CoV-2 aggravates cellular metabolism mediated complications in COVID-19 infection. Dermatol Ther. 2020;33:13871.

Yang Z, Shi J, He Z, Lü Y, Xu Q, Ye C, et al. Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients. Aging. 2020;12(7):6037-48.

Zou Z, Yan Y, Shu Y, Gao R, Sun Y, Li X, et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun. 2014;5:3594.

Huang F, Guo J, Zou Z, Liu J, Cao B, Zhang S, et al. Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nat Commun. 2014;5:3595.

Gomolak JR, Didion SP. Angiotensin II-induced endothelial dysfunction is temporally linked with increases in interleukin-6 and vascular macrophage accumulation. Front Physiol. 2014;5:396.

Calo LA, Rigato M, Bertoldi G. ACE2/angiotensin 1-7 protective anti-inflammatory and antioxidant role in hyperoxic lung injury: support from studies in Bartter’s and Gitelman’s syndromes. QJM Int J Med. 2020;113(6):440-1.

Mendoza-Torres E, Oyarzun A, Mondaca-Ruff D, Azocar A, Castro PF, Jalil JE, et al. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. Ther Adv Cardiovasc Dis. 2015;9(4):217-37.

Arendse LB, Danser AHJ, Poglitsch M, Touyz RM, Burnett JC, Llorens-Cortes C, et al. Novel therapeutic approaches targeting the renin–angiotensin system and associated peptides in hypertension and heart failure. Pharmacol Rev. 2019;71(4):539-70.

Prestes TRR, Rocha NP, Miranda A, Teixeira AL, Simoes-E-Silva AC. The anti-inflammatory potential of ACE2/angiotensin(1-7)/Mas receptor axis: evidence from basic and clinical research. Curr Drug Targets. 2017;18(11):1301-13.

Qaradakhi T, Apostolopoulos V, Zulli A. Angiotensin (1-7) and alamandine: similarities and differences. Pharmacol Res. 2016;111:820-6.

Hrenak J, Paulis L, Simko F. Angiotensin A/alamandine/MrgD axis: another clue to understanding cardiovascular pathophysiology. Int J Mol Sci. 2016;17(7):1098.

Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is there an association between COVID-19 mortality and the renin–angiotensin system-a call for epidemiologic investigations. Clin Infect Dis. 2020;71(15):870-4.




How to Cite

Sahoo, S., T., S., V., S. K., & N., L. (2021). Could homocysteine, angiotensin and alamandine be used as potential biomarkers in management of COVID-19?. International Journal of Research in Medical Sciences, 9(6), 1834–1839.



Review Articles